Alnylam Pharmaceuticals Inc. share price logo

Alnylam Pharmaceuticals Inc.

NASDAQ: ALNY

Large Cap

$278.09

-4.63

(-1.64%)

as on

Alnylam Pharmaceuticals Inc. Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $273.11
    $279.93
    downward going graph

    1.79%

    Downside

    0.66%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $273.11
    $495.55
    downward going graph

    1.79%

    Downside

    78.20%

    Upside

    downward going graph

Alnylam Pharmaceuticals Inc. share price movements today

Previous Close
$282.72
Open
$278.33
Volume
956.0K
Day's Low - High
$273.11 - $279.93
52 Week Low - High
$273.11 - $495.55

Alnylam Pharmaceuticals Inc. Historical Returns

1 Month Return
-5.51 %
3 Month Return
-10.61 %
1 Year Return
-10.96 %
3 Year Return
+ 37.96 %
5 Year Return
+ 57.21 %

Alnylam Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Alnylam Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$37.7B

EPS (TTM)

9.505

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

71.21

Industry PE ratio

-4.0832

PEG Ratio

0.4826

EBITDA

806.9M

Revenue (TTM)

4.3B

Profit Margin

12.55%

Return On Equity TTM

90.36%

Alnylam Pharmaceuticals Inc. Stock Valuation

Track how Alnylam Pharmaceuticals Inc. P/E has moved over time to understand its valuation trends.

Alnylam Pharmaceuticals Inc. in the last 5 years

  • Overview

  • Trends

Lowest (-99.61x)

December 31, 2023

Industry (-4.08x)

June 19, 2026

Today (71.21x)

June 19, 2026

Highest (124.53x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 71.21x

Alnylam Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alnylam Pharmaceuticals Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Alnylam Pharmaceuticals Inc. Stock including INR - Dollar returns

The Alnylam Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Alnylam Pharmaceuticals Inc. investment value today

Current value as on today

₹96,699

Returns

-₹3,301

(-3.3%)

Returns from Alnylam Pharmaceuticals Inc. Stock

-₹10,960 (-10.96%)

Dollar Impact

₹7,659 (+7.66%)

Analyst Recommendation on Alnylam Pharmaceuticals Inc. Stock

Based on 34 analysts

BUY

70.59%

Buy

29.41%

Hold

0.00%

Sell

Based on 34 analysts, 70.59% of analysts recommend a 'BUY' rating for Alnylam Pharmaceuticals Inc.. Average target price of $438.52

Alnylam Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Alnylam Pharmaceuticals Inc..

What analysts predicted

36.58%UPSIDE

Target Price

$438.52

Current Price

$278.09

Analyzed by

34 Analysts

Target

$438.52

Alnylam Pharmaceuticals Inc. target price $438.52, a slight upside of 36.58% compared to current price of $278.09. According to 34 analysts rating.

Indian Investors' Interest in Alnylam Pharmaceuticals Inc. Stock

Investment in Alnylam Pharmaceuticals Inc. Shares on INDmoney has grown by 42.04% in the last 30 days, indicating increased investment activity.

Time period: to

Change:42.04% versus previous 30 day period

Alnylam Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
439
494
659
500
593
594
773
1,249
1,097
1,167
Gross Profit
353
428
591
415
490
523
630
1,051
829
956
Operating Income
-116
-43
48
-76
-105
18
-16
367
131
268
EBITDA
-92
-14
37
-60
-140
11
18
297
303
304
Interest Expense
31
35
33
34
38
38
40
44
129
69
Depreciation
23
25
24
27
-20
14
13
13
13
13
Income Before Tax
-137
-63
-11
-108
-193
-41
-35
238
161
221
Income Tax Expense
0
2
5
2
-110
15
30
-12
-25
-15
Net Income
-137
-65
-16
-111
-83
-57
-66
251
186
205
Net Profit Margin
-31.35%
-13.34%
-2.56%
-22.27%
-14.12%
-9.67%
-8.57%
20.10%
16.99%
17.65%

Alnylam Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
47
89
74
219
492
844
1,037
1,828
2,248
3,713
Gross Profit
47
89
73
194
414
704
868
1,517
1,924
3,036
Operating Income
-424
-500
-814
-939
-828
-708
-785
-282
-176
501
EBITDA
-409
-486
-754
-885
-736
-661
-926
-258
-178
631
Interest Expense
8
12
29
108
84
143
155
121
141
252
Depreciation
-
13
6
54
74
89
85
97
56
55
Income Before Tax
-410
-490
-760
-885
-855
-852
-1,126
-433
-377
323
Income Tax Expense
-23
-25
0
0
2
0
4
6
-99
9
Net Income
-410
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Net Profit Margin
-869.63%
-545.95%
-1016.58%
-403.24%
-174.15%
-101.01%
-109.04%
-24.08%
-12.37%
8.45%

Alnylam Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-65
-16
-111
-83
-57
-66
251
186
205
Operating Cash Flow
-81
124
43
-94
-118
153
325
163
70
Investing Cash Flow
-67
33
-30
-52
113
-141
501
-37
-25
Financing Cash Flow
28
131
102
30
44
53
-448
45
15
Change in Cash
-130
286
131
-133
53
93
376
166
53

Alnylam Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-490
-761
-886
-858
-852
-1,131
-440
-278
313
Operating Cash Flow
-382
-562
-278
-614
-641
-541
104
-8
524
Investing Cash Flow
-290
272
-417
-435
-273
169
-336
-116
436
Financing Cash Flow
1,124
65
823
994
1,247
425
172
294
-305
Change in Cash
451
-224
126
-50
323
46
-53
153
690

Mutual Funds that own Alnylam Pharmaceuticals Inc. Stock

Check out the Mutual Funds with significant holdings in Alnylam Pharmaceuticals Inc..

Funds
Holdings
Shares Held
ICICI Prudential NASDAQ 100 Index Fund Direct Growth
ICICI Prudential NASDAQ 100 Index Fund Direct Growth
0.1757%
2214

Global Institutional Holdings in Alnylam Pharmaceuticals Inc.

Funds
Holdings
Dodge & Cox
1.45%
Winslow Capital Management, LLC
0.9%
American Century Companies Inc
1.35%
Capital Research Global Investors
7.1%
JPMorgan Chase & Co
4.74%
See all

Alnylam Pharmaceuticals Inc. News & Key Events

  • img

    Today's Timeline - 09 June

    Tue, 10:25 PM

    -

    Alnylam targets 25% revenue CAGR and 30% operating margin by 2030, focusing on AMVUTTRA and pipeline expansion.

Insights on Alnylam Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ALNY has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 186.41M → 205.99M (in $), with an average increase of 9.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.09B → 1.16B (in $), with an average increase of 6.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 18.8% return, outperforming this stock by 29.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, ALNY stock has moved down by -30.5%

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
OrganisationAlnylam Pharmaceuticals Inc.
Headquarters675 West Kendall Street, Cambridge, MA, United States, 02142
IndustryBiotechnology
CEODr. Yvonne L. Greenstreet M.B.A., M.D.
E-voting on sharesClick here to vote

Key Management of Alnylam Pharmaceuticals Inc.

Name

Title

Dr. Phillip A. Sharp Ph.D.

Co-Founder, Member of the Scientific Advisory Board

Mr. Jeffrey V. Poulton M.B.A.

CFO & Executive VP

Mr. Bryan Andrew Supran J.D.

Chief Legal Officer

Dr. Pushkal P. Garg M.D.

Executive VP & Chief Research & Development Officer

Mr. Tolga Tanguler M.B.A.

Executive VP & Chief Commercial Officer

Mr. Timothy J. Maines

Chief Technical Operations & Quality Officer

Mr. Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Dr. Yvonne L. Greenstreet M.B.A., M.D.

CEO & Director

Ms. Christine Regan Akinc

Chief Corporate Communications Officer

Dr. Kevin Joseph Fitzgerald Ph.D.

Executive VP, Chief Scientific Officer and Head of Early Research & Early Development

FAQs

What is Alnylam Pharmaceuticals Inc. share price today?

Alnylam Pharmaceuticals Inc. share price today is $278.09 as on at the close of the market. Alnylam Pharmaceuticals Inc. share today touched a day high of $279.93 and a low of $273.11.

What is the 52 week high and 52 week low for Alnylam Pharmaceuticals Inc. share?

Alnylam Pharmaceuticals Inc. share touched a 52 week high of $495.55 on and a 52 week low of $273.11 on . Alnylam Pharmaceuticals Inc. stock price today i.e. is closed at $278.09,which is 43.88% down from its 52 week high and 1.82% up from its 52 week low.

What is Alnylam Pharmaceuticals Inc.'s market capitalisation today?

Alnylam Pharmaceuticals Inc. market capitalisation is $0.04T as on .

How to invest in Alnylam Pharmaceuticals Inc. Stock (ALNY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alnylam Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alnylam Pharmaceuticals Inc. Shares that will get you 0.0054 shares as per Alnylam Pharmaceuticals Inc. share price of $278.09 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Alnylam Pharmaceuticals Inc. Stock (ALNY) from India?

Indian investors can start investing in Alnylam Pharmaceuticals Inc. (ALNY) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Alnylam Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Alnylam Pharmaceuticals Inc. share’s latest price of $278.09 as on June 19, 2026 at 8:45 am IST, you will get 0.0360 shares of Alnylam Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Alnylam Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Alnylam Pharmaceuticals Inc. stock has given 57.21% share price returns and 27.56% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?